A new research study could redefine treatment for disease
(Vocus/PRWEB ) June 17, 2008 -- Americans are living longer, but living longer means our aging population is at greater risk for acquiring disease. For those with high cholesterol, diabetes and high blood pressure, Peripheral Artery Disease (PAD) is of particular concern.
PAD, often described as “poor circulation,” is diagnosed when the large arteries of the leg narrow thereby restricting blood flow. The tissues then become starved of the blood, nutrients, and oxygen they need, and in its most advanced form, skin ulcers begin to develop. At this stage of PAD, called Critical Limb Ischemia (CLI), the health threat is serious.
The threat is so serious that it is difficult to grasp, but here are the facts: PAD at the stage of Critical Limb Ischemia presents the likelihood of amputation or even death. At this time, there are no prescription drugs available to effectively treat Critical Limb Ischemia, and there are limited treatments available that will delay or prevent amputation.
While these facts present a grim outlook, there is hope, thanks to a unique new opportunity. Catherine Wittgen, MD is currently conducting an investigational research study for PAD at the stage of Critical Limb Ischemia with foot and/or leg ulcers. It is anticipated that the investigational study medication may promote new blood vessel growth, and may delay the time to amputation and/or death.
The research study is currently seeking qualified participants. Individuals must be: 50 years of age or older with stable skin ulcers or non-infected gangrene on a foot or leg; diagnosed with Peripheral Arterial Disease (PAD) at the stage of Critical Limb Ischemia; and be unsuitable for by-pass or revascularization. Additional criteria also apply.
If you or someone you know suffers with skin ulcers due to PAD at the stage of Critical Limb Ischemia, please call us to determine eligibility at 1-888-853-4656 or visit our web site at www.tamarisstudy.com.
This research study is now underway throughout the United States, including the St. Louis area.
Today’s research touches our future . . . and there is a possibility that the information obtained in this study may help in the future development of a new therapy for those who suffer from Critical Limb Ischemia with foot and/or leg ulcers. For more information, please contact Hal Coxon at (847) 919-1005 or via email at halcoxon @ axmarketing.com.
Contact:
Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005
halcoxon @ axmarketing.com
www.tamarisstudy.com